Natural History and Prognosis of Hepatitis B

 

 Buy Article Permissions and Reprints

ABSTRACT

The natural history of hepatitis B virus (HBV) infection is complex and variable and is greatly influenced by the age at infection, the level of HBV replication, and host immune status. Chronic HBV infection generally consists of an early replicative phase with active liver disease (hepatitis B e antigen [HBeAg]-positive chronic hepatitis) and a late low or nonreplicative phase with HBeAg seroconversion and remission of liver disease (inactive carrier state). After HBeAg seroconversion, some patients may have active hepatitis due to HBV variants not expressing HBeAg (HBeAg-negative chronic hepatitis). Morbidity and mortality are linked to development of cirrhosis and hepatocellular carcinoma. Survival is reasonably good (about 85% probability at 5 years) in compensated cirrhosis but very poor in decompensated cirrhosis. Both cirrhotic and noncirrhotic patients with sustained reduction of HBV replication and normalization of aminotransferase after interferon alfa therapy have a reduced risk for liver-related complications.

REFERENCES

• 1 Maddrey W C. Hepatitis B: an important public health issue.  J Med Virol . 2000;  61 362-366
  CrossrefPubMedGoogle Scholar
• 2 Lee W M. Hepatitis B virus infection.  N Engl J Med . 1997;  337 1733-1745
  CrossrefPubMedGoogle Scholar
• 3 Lok A S, Heathcote E J, Hoofnagle J H. Management of hepatitis B: 2000-summary of a workshop.  Gastroenterology . 2001;  120 1828-1853
  PubMedGoogle Scholar
• 4 Lok A SF, McMahon B J. Chronic hepatitis B.  Hepatology . 2001;  34 1225-1241
  CrossrefPubMedGoogle Scholar
• 5 Milich D R, Chen M K, Hughes J L, Jones J E. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence.  J Immunol . 1998;  160 2013-2021
  PubMedGoogle Scholar
• 6 Hadziyannis S J, Vassilopoulos D. Hepatitis B e antigen- negative chronic hepatitis B.  Hepatology . 2001;  34 617-624
  CrossrefPubMedGoogle Scholar
• 7 Chemin I, Zoulim F, Merle P. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology.  J Hepatol . 2001;  34 471-473
  CrossrefPubMedGoogle Scholar
• 8 Kawatani T, Suou T, Tajima F. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies.  Eur J Haematol . 2001;  67 45-50
  CrossrefPubMedGoogle Scholar
• 9 McMahon B J, Alward W LM, Hall D B. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state.  J Infect Dis . 1985;  151 599-603
  PubMedGoogle Scholar
• 10 Smedile A, Farci P, Verme G. Influence of delta infection on severity of hepatitis B.  Lancet . 1982;  2 945-947
  PubMedGoogle Scholar
• 11 Feray C, Gigou M, Samuel D. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis.  Gastroenterology . 1993;  104 549-555
  PubMedGoogle Scholar
• 12 Chang M H. Natural history of hepatitis B infection in children.  J Gastroenterol Hepatol . 2000;  15(Suppl) E11-E19
  CrossrefPubMedGoogle Scholar
• 13 Tassopoulos N C, Papaevangelou G J, Sjogren M H. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults.  Gastroenterology . 1987;  92 1844-1850
  PubMedGoogle Scholar
• 14 Burk R D, Hwang L Y, Ho G YF, Shafritz D A, Beasley R P. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load.  J Infect Dis . 1994;  170 1418-1423
  CrossrefPubMedGoogle Scholar
• 15 Cacciola I, Cerenzia G, Pollicino T. Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection.  J Hepatol . 2002;  36 426-432
  CrossrefPubMedGoogle Scholar
• 16 Lok A SF, Lai C L, Wu P C, Leung E KY, Lam T S. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection.  Gastroenterology . 1987;  92 1839-1843
  PubMedGoogle Scholar
• 17 Realdi G, Alberti A, Rugge M. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection.  Gastroenterology . 1980;  79 195-199
  PubMedGoogle Scholar
• 18 Hoofnagle J H, Dusheiko G M, Seef L B. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis.  Ann Intern Med . 1981;  94 744-748
  PubMedGoogle Scholar
• 19 Fattovich G, Rugge M, Brollo L. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B.  Hepatology . 1986;  6 167-172
  PubMedGoogle Scholar
• 20 Liaw Y F, Tai D I, Chu C M, Chen T J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study.  Hepatology . 1988;  8 493-496
  PubMedGoogle Scholar
• 21 Moreno-Otero R, Garcia-Monzòn C, Garcia-Sànchez A. Development of cirrhosis after chronic type B hepatitis: a clinicopathologic and follow-up study of 46 HBeAg-positive asymptomatic patients.  Am J Gastroenterol . 1991;  86 560-564
  PubMedGoogle Scholar
• 22 Zarski J P, Marcellin P, Cohard M. Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France.  J Hepatol . 1994;  20 636-640
  CrossrefPubMedGoogle Scholar
• 23 Di Marco V, Lo Iacono O, Cammà C. The long-term course of chronic hepatitis B.  Hepatology . 1999;  30 257-264
  CrossrefPubMedGoogle Scholar
• 24 Lin S M, Sheen I S, Chien R N, Chu C M, Liaw Y F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.  Hepatology . 1999;  29 971-975
  CrossrefPubMedGoogle Scholar
• 25 Yuen M F, Hui C K, Cheng C C. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.  Hepatology . 2001;  34 139-145
  CrossrefPubMedGoogle Scholar
• 26 Chang M H, Hsu H Y, Hsu H C. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age.  Hepatology . 1995;  22 1387-1392
  CrossrefPubMedGoogle Scholar
• 27 Bortolotti F, Jara P, Crivellaro C. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period.  J Hepatol . 1998;  29 184-190
  CrossrefPubMedGoogle Scholar
• 28 Hsu Y S, Chien R N, Yeh C T. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.  Hepatology . 2002;  35 1522-1527
  CrossrefPubMedGoogle Scholar
• 29 Fong T L, Di Bisceglie M A, Gerber M A, Waggoner J G, Hoofnagle J H. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B.  Hepatology . 1993;  18 1313-1318
  CrossrefPubMedGoogle Scholar
• 30 McMahon B J, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus.  Ann Intern Med . 2001;  135 759-768
  CrossrefPubMedGoogle Scholar
• 31 Bortolotti F, Cadrobbi P, Crivellaro C. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood.  Gastroenterology . 1990;  99 805-810
  PubMedGoogle Scholar
• 32 Wong D KH, Cheung A M, O'Rourke K. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.  Ann Intern Med . 1993;  119 312-323
  PubMedGoogle Scholar
• 33 Vajro P, Migliaro F, Fontanella A, Orso G. Interferon: a meta-analysis of published studies in pediatric chronic hepatitis B.  Acta Gastroenterol Belg . 1998;  61 219-223
  PubMedGoogle Scholar
• 34 Chang M H, Sung J L, Lee C Y. Factors affecting clearance of hepatitis B e antigen in hepatitis B surface antigen carrier children.  J Pediatr . 1989;  115 385-390
  PubMedGoogle Scholar
• 35 Alward W LM, McMahon B J, Hall D B. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma.  J Infect Dis . 1985;  151 604-609
  PubMedGoogle Scholar
• 36 Liaw Y F. Current trends in therapy for chronic viral hepatitis.  J Gastroenterol Hepatol . 1997;  12 S346-S353
  PubMedGoogle Scholar
• 37 Perillo R P. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease.  Gastroenterology . 2001;  120 1009-1022
  CrossrefPubMedGoogle Scholar
• 38 Orito E, Mizokami M, Sakugawa H. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotype B and C. Japan HBV Genotype Research Group.  Hepatology . 2001;  33 218-223
  CrossrefPubMedGoogle Scholar
• 39 Chu C J, Hussain M, Lok A SF. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared to hepatitis B virus genotype C.  Gastroenterology . 2002;  122 1756-1762
  CrossrefPubMedGoogle Scholar
• 40 Chan H LY, Leung N WY, Hussain M, Wong M L, Lok A SF. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong.  Hepatology . 2000;  31 763-768
  CrossrefPubMedGoogle Scholar
• 41 Funk M L, Rosenberg D M, Lok A SF. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants.  J Viral Hepat . 2002;  9 52-61
  CrossrefPubMedGoogle Scholar
• 42 Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine.  J Med Virol . 2000;  61 398-402
  CrossrefPubMedGoogle Scholar
• 43 Fattovich G, Farci P, Rugge M. Randomized controlled trial of lymphoblastoid interferon alfa in patients with chronic hepatitis B who lacked hepatitis B e antigen.  Hepatology . 1992;  15 584-589
  PubMedGoogle Scholar
• 44 Lampertico P, Del Ninno E, Manzin A. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum.  Hepatology . 1997;  26 1621-1625
  PubMedGoogle Scholar
• 45 Tassopoulos N C, Volpes R, Pastore G. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Group.  Hepatology . 1999;  29 889-896
  CrossrefPubMedGoogle Scholar
• 46 Brunetto M R, Oliveri F, Coco B. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study.  J Hepatol . 2002;  36 263-270
  PubMedGoogle Scholar
• 47 Papatheodoridis G V, Manesis E, Hadziyannis S J. The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B.  J Hepatol . 2001;  34 306-313
  CrossrefPubMedGoogle Scholar
• 48 De Franchis R, Meucci G, Vecchi M. The natural history of asymptomatic hepatitis B surface antigen carriers.  Ann Intern Med . 1993;  118 191-194
  PubMedGoogle Scholar
• 49 Bellentani S, Dal Molin G, Miglioli L. Natural history of HBV infection: a 9 years follow-up of the Dionysos cohort.  J Hepatol . 2002;  36(Suppl 1) 228
  PubMedGoogle Scholar
• 50 Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm S W. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa.  Hepatology . 1997;  26 1338-1342
  CrossrefPubMedGoogle Scholar
• 51 Fattovich G, Giustina G, Sanchez-Tapias J. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis.  Am J Gastroenterol . 1998;  93 896-900
  CrossrefPubMedGoogle Scholar
• 52 McMahon B J, Alberts S R, Wainwright R B, Bulkow L, Lanier A P. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska Native carriers.  Arch Intern Med . 1990;  150 1051-1054
  CrossrefPubMedGoogle Scholar
• 53 Huo T I, Wu J C, Lee P C. Sero-clearance of hepatitis B surface antigen in chronic carriers not necessarily implies a good prognosis.  Hepatology . 1998;  28 231-236
  CrossrefPubMedGoogle Scholar
• 54 Fattovich G, Brollo L, Giustina G. Natural history and prognostic factors of chronic hepatitis type B.  Gut . 1991;  32 294-298
  PubMedGoogle Scholar
• 55 Ikeda K, Saitoh S, Suzuki Y. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation in 2215 patients.  J Hepatol . 1998;  28 930-938
  CrossrefPubMedGoogle Scholar
• 56 Mazzella G, Saracco G, Festi D. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial.  Am J Gastroenterol . 1999;  94 2246-2250
  CrossrefPubMedGoogle Scholar
• 57 Fattovich G, Brollo L, Alberti A. Long term follow-up of anti-HBe positive chronic active hepatitis B.  Hepatology . 1988;  8 1651-1654
  PubMedGoogle Scholar
• 58 Brunetto M R, Oliveri F, Rocca G. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen.  Hepatology . 1989;  10 198-202
  PubMedGoogle Scholar
• 59 Kao J H, Chen P J, Lai M Y, Chen D S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B.  Gastroenterology . 2000;  118 554-559
  CrossrefPubMedGoogle Scholar
• 60 Chan H L, Tsang S W, Liew C T. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection.  Am J Gastroenterol . 2002;  97 406-412
  CrossrefPubMedGoogle Scholar
• 61 Fattovich G, Tagger A, Brollo L. A Hepatitis C virus infection in chronic hepatitis B virus carriers.  J Infect Dis . 1991;  163 400-402
  PubMedGoogle Scholar
• 62 Fong T L, Di Bisceglie M A, Waggoner J G, Banks S M, Hoofnagle J H. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B.  Hepatology . 1991;  14 64-67
  PubMedGoogle Scholar
• 63 Sagnelli E, Coppola N, Scolastico C. Virologic and clinical expression of reciprocal inhibitory effect of hepatitis B, C and delta viruses in patients with chronic hepatitis.  Hepatology . 2000;  32 1106-1110
  CrossrefPubMedGoogle Scholar
• 64 Gaeta G B, Stroffolini T, Chiaramonte M. Chronic hepatitis D: a vanishing disease?.  <~>An Italian multicenter study. Hepatology . 2000;  32 824-827
  CrossrefPubMedGoogle Scholar
• 65 Fattovich G, Boscaro S, Noventa F. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B.  J Infect Dis . 1987;  155 931-935
  CrossrefPubMedGoogle Scholar
• 66 Rosina F, Conoscitore P, Cuppone R. Changing pattern of chronic hepatitis D in Southern Europe.  Gastroenterology . 1999;  117 161-166
  CrossrefPubMedGoogle Scholar
• 67 Colin J F, Cazals-Hatem D, Loriot M A. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.  Hepatology . 1999;  29 1306-1310
  CrossrefPubMedGoogle Scholar
• 68 Liaw Y F, Lin D Y, Chen T J, Chu C M. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study.  Liver . 1989;  9 235-241
  PubMedGoogle Scholar
• 69 Kato Y, Nakata K, Omagari K. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses.  Cancer . 1994;  74 2234-2238
  PubMedGoogle Scholar
• 70 Mazzella G, Accogli E, Sottili S. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.  J Hepatol . 1996;  24 141-147
  CrossrefPubMedGoogle Scholar
• 71 Ikeda K, Saitoh S, Suzuki Y. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus.  Cancer . 1998;  82 827-835
  CrossrefPubMedGoogle Scholar
• 72 Fattovich G, Giustina G, Christensen E. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B.  Gut . 2000;  46 420-426
  CrossrefPubMedGoogle Scholar
• 73 Realdi G, Fattovich G, Hadziyannis S. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study.  J Hepatol . 1994;  21 656-666
  CrossrefPubMedGoogle Scholar
• 74 Beasley R P. Hepatitis B virus. The major etiology of hepatocellular carcinoma.  Cancer . 1988;  61 1942-1956
  PubMedGoogle Scholar
• 75 Yu M W, Hsu F C, Sheen I S. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers.  Am J Epidemiol . 1997;  145 1039-1047
  PubMedGoogle Scholar
• 76 McMahon B J, Bulkow L, Harpster A. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population based study.  Hepatology . 2000;  32 842-846
  CrossrefPubMedGoogle Scholar
• 77 Liaw Y F, Tai D I, Chu C M. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study.  Gastroenterology . 1985;  90 263-267
  PubMedGoogle Scholar
• 78 Oon C J. Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions.  Cancer Chemother Pharmacol . 1992;  31(Suppl 1) S137-S142
  CrossrefPubMedGoogle Scholar
• 79 Fattovich G, Pantalena M, Zagni I. Effect of hepatitis B and C virus infection on the natural history of compensated cirrhosis: a cohort study of 297 patients.  Am J Gastroenterol . 2002;  97 2886-2895
  CrossrefPubMedGoogle Scholar
• 80 Fattovich G, Giustina G, Schalm S W. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B.  Hepatology . 1995;  21 77-82
  CrossrefPubMedGoogle Scholar
• 81 Benvegnù L, Fattovich G, Noventa F. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis.  Cancer . 1994;  74 2442-2448
  CrossrefPubMedGoogle Scholar
• 82 Chung H T, Lai C L, Lok A S. Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis.  Hepatology . 1995;  22 25-29
  CrossrefPubMedGoogle Scholar
• 83 De Jongh E F, Janssen H LA, De Man A R. M.  Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology . 1992;  103 1630-1635
  PubMedGoogle Scholar
• 84 Hui A Y, Chan H L, Leung N W. Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation.  J Clin Gastroenterol . 2002;  34 569-572
  CrossrefPubMedGoogle Scholar
• 85 Hoofnagle J H, Di Bisceglie M A. The treatment of chronic viral hepatitis.  N Engl J Med . 1997;  336 347-356
  PubMedGoogle Scholar
• 86 Evans A A, Fine M, London W T. Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: implications for interferon therapy.  J Infect Dis . 1997;  176 845-850
  PubMedGoogle Scholar
• 87 Manesis E K, Hadziyannis S J. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.  Gastroenterology . 2001;  121 101-109
  CrossrefPubMedGoogle Scholar
• 88 Lampertico P, Viganò M, Iavarone M, Del Ninno E, Colombo M. Long-term outcome of patients with HBeAg-negative chronic hepatitis B treated with a 24-month course of interferon alfa.  J Hepatol . 2001;  34(Suppl 1) 149
  PubMedGoogle Scholar
• 89 Niederau C, Heintges T, Lange S. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.  N Engl J Med . 1996;  334 1422-1427
  CrossrefPubMedGoogle Scholar
• 90 EUROHEP: European Concerted Action on HBV-related Cirrhosis 2003. Updated analysis, data on file: Fattovich et al50
  Google Scholar
• 91 International Interferon-α Hepatocellular Carcinoma Study Group. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study.  Lancet . 1998;  351 1535-1539
  CrossrefPubMedGoogle Scholar
• 92 Lau D TY, Everhart J, Kleiner D E. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa.  Gastroenterology . 1997;  113 1660-1667
  PubMedGoogle Scholar
• 93 Yao F Y, Terrault N A, Freise C, Maslow L, Bass N M. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.  Hepatology . 2001;  34 411-416
  CrossrefPubMedGoogle Scholar
• 94 Mutimer D. Beneficial effect of lamivudine for hepatitis B transplant recipients.  Liver Transp . 2002;  8 440-442
  PubMedGoogle Scholar